小细胞肺癌概况及治疗进展 .PPTVIP

拓扑特肯 +紫杉醇与顺铂+VP16及同步放疗交替治疗初治局限期SCLC:I 期临床试验 Escalating doses of topotecan (0.8-1.4 mg/m(2) d1-5) and paclitaxel (110-175 mg/m(2) d1) were administered i.v. every 21 days for two cycles followed by two cycles of etoposide (120 mg/m(2) d1-3) and cisplatin (60 mg/m(2) d1) with thoracic radiotherapy. Two additional cycles of chemotherapy (topotecan and paclitaxel, followed by etoposide and cisplatin) were given. The result grade /=3 neutropenia in 67% of courses of topotecan and paclitaxel and grade /=2 esophagitis in 71% of patients. Two patient died. Response rates after induction of topotecan and paclitaxel: 16 of 18 (88.8%) partial response, 1 of 18 (5.5%) complete response. Response rates after completion of therapy: 10 of 18 (55.5%) partial response, 7 of 18 (38.8%) complete response. 拓扑特肯日剂量与连续静脉灌注治疗SCLC的II期临床 20 case of 1.5 mg/m2 daily for 5 days every 3 weeks . an average of 5 courses (range: 1-13) . 20 case of 1.3 mg/m2 per day over 72 hours administered intravenously every 4 weeks . an average of 2 courses (range: 1-7) 拓扑特肯日剂量与连续静脉灌注治疗SCLC的II期临床 Confirmed response rates for the daily and continuous-infusion schedules are 62.5% (90% CI: 49-75%) and 15% (90% CI: 1-29%), respectively grade /=3 neutropenia was 92% (55/60) and grade /=3 leukopenia was 58% (35/60). Nonhematologic toxicity was very mild, with only 10% (6/60) patients experiencing grade4 toxicities. 拓扑特肯联合紫杉醇治疗初治的广泛期SCLC的II期临床 untreated ED-SCLC patients ,Eastern Coperative Oncology Group performance status 2 topotecan 1 mg/m2, on days 1-5, and paclitaxel 135 mg/m2 over 24 h on day 5, every 4 weeks. Prophylactic granulocyte colony-stimulating factor was administered to all patients 拓扑特肯联合紫杉醇治疗初治的广泛期SCLC的II期临床 a median of four cycles chemotherapy Grade 4 anemia, neutropenia and thrombocytopenia occurred in 13, 31 and 18 patients, respectively 26 Of 32 patients eligible for response evaluation, there were six complete and 12 partial responses (overall response rate 69%). The median surviva